Prevalence: Hepatitis B (HBV, B型肝炎) and Hepatitis C (HCV, C型肝炎) are highly prevalent in Malaysia and in Pahang. It is estimated there are about 250,000 adults who are HBV carrier (prevalence rate 1.5%; children are relatively free of HBV because of vaccination which was introduced since 1989) and another 400,000 people have been infected by HCV (prevalence rate 2%).
Health consequences: Untreated, both HBV and HCV will lead to chronic liver disease/cirrhosis (CLD, 肝硬化) and liver cancer (HCC, 肝癌). Each year in Malaysia, about 1500 people died of CLD. Globocan12  estimated another 1750 people died of liver cancer, the 4th most common cause of cancer death in Malaysia after Lung, Breast and Colon.
Access to treatment: As a result of advances in medical sciences in the past decades, both HBV and HCV are now treatable; HCV in particular is curable with modern Direct Acting Anti-Viral (DAA) therapies Yet, in spite of being an upper middle income country, screening services for HBV and HCV in Malaysia remain under-developed, and access to modern anti-viral therapies is even more limited